CNBX Pharmaceuticals Inc.
CNBX · OTCMCIK 1343009fmd_0BS8ZA60Q95WVSHEK67EDWQB29Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Sep 15, 2004 to May 31, 2026, 69 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net interest income | – | – | 0 | (0) | – | – | – | – | (0) | (0) |
| Gross profit | 0 | 0 | – | – | – | – | – | – | – | – |
| Realized investment gains (losses) | – | – | 0 | 0 | 0 | 0 | 0 | – | – | – |
| Research and development | 0 | 0 | 1 | 2 | 2 | 2 | 1 | 0 | 0 | 0 |
| Selling, general and administrative | 0 | 2 | 3 | 2 | 1 | 1 | – | – | – | – |
| Total operating expenses | 0 | 2 | 4 | 3 | 3 | 3 | 3 | 1 | 1 | 0 |
| Compensation and benefits | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | (0) | (2) | (4) | (3) | (3) | (3) | (3) | (1) | (1) | (0) |
| Interest expense | 0 | 0 | 0 | – | – | – | – | – | – | 0 |
| Other non-operating income (expense) | (0) | (0) | 0 | 4 | (4) | 1 | 1 | 0 | 0 | 0 |
| Income before taxes | – | – | – | – | – | – | – | – | – | – |
| Income tax expense | – | – | – | – | – | – | – | – | – | – |
| Net income from continuing operations | – | – | – | – | – | – | – | – | – | – |
| Net income | (0) | (2) | (4) | 1 | (7) | (3) | (4) | (4) | (1) | (0) |